Peyronie’s disease: A contemporary review of non-surgical treatment

Peer review under responsibility of Arab Association of Urology.

Figures & data

Table 1 Oral therapies for PD.

Treatment (dose)	Mechanism of action	Efficacy	ICSM guideline [15]
Vitamin E (400 IU daily to twice daily)	Antioxidant reduces oxidative stress of reactive oxygen species shown to be increased in PD	NB for pain, curvature, or plaque size	NB for deformity
Colchicine (2.5 mg daily)	Inhibits fibrosis and collagen deposition by inhibiting neutrophil microtubules	NB for pain, curvature, or plaque size	NB for deformity
Potassium aminobenzoate (3 g every 6 h)	Stabilises tissue serotonin monoamine oxidase activity; antifibrotic effect due to a direct inhibitory effect on fibroblast glycosaminoglycan secretion	Mean decrease in plaque size in 74.3%, no improvement in curvature	NB for deformity
Tamoxifen (40 mg daily)	Affects the release of TGF from fibroblasts and blocks TGF receptors	No demonstrable improvement in pain, curvature, or plaque size	NB for deformity
Carnitine (1 g twice daily)	Reduces both collagen fibre deposition and elastogenesis	No significant improvement in pain, curvature or plaque size	NB for deformity
Pentoxifylline (400 mg twice daily)	Nonspecific phosphodiesterase inhibitor, antifibrotic presumably	36.9% with mean decrease in curvature of 23°	Further studies required to confirm findings

NB, no benefit; TGF, transforming growth factor.